Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses

Journal of Immunology

Volumn 181, Issue 2, 2008, Pages 1386-1398

  Banerjee, Antara ^a   De, Manjarika ^a   Ali, Nahid ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; LIPOSOME; NITRIC OXIDE; OCTADECYLAMINE; TUMOR NECROSIS FACTOR ALPHA; ANTIPROTOZOAL AGENT; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLEARANCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DISEASE MODEL; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; IMMUNOMODULATION; IMMUNOSTIMULATION; INFECTION PREVENTION; LIVER CLEARANCE; LOW DRUG DOSE; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PARASITE IDENTIFICATION; PRIORITY JOURNAL; REINFECTION; RELAPSE; SECRETORY CELL; SINGLE DRUG DOSE; SPLEEN; SPLEEN CELL; SUPERNATANT; TREATMENT OUTCOME; UPREGULATION; VISCERAL LEISHMANIASIS; ANIMAL; BAGG ALBINO MOUSE; DRUG COMBINATION; IMMUNOLOGY; LEISHMANIA DONOVANI; LIVER; METABOLISM; PARASITOLOGY; T LYMPHOCYTE;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CYTOKINES; DOWN-REGULATION; DRUG THERAPY, COMBINATION; INTERLEUKIN-10; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIPOSOMES; LIVER; MICE; MICE, INBRED BALB C; NITRIC OXIDE; SPLEEN; T-LYMPHOCYTES;

EID: 49049086135     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.2.1386     Document Type: Article

References (74)

1. Coler, R. N., and S. G. Reed. 2005. Second-generation vaccines against leishmaniasis. Trends Parasitol. 21: 244-249.
2. Dowlati, Y. 1996. Treatment of cutaneous leishmaniasis (Old World). Clin. Dermatol. 14: 513-517. (Pubitemid 26327745)
3. Croft, S. L., K. Seifert, and V. Yardley. 2006. Current scenario of drug development for leishmaniasis. Indian J. Med. Res. 123: 399-410. (Pubitemid 43905578)
4. Melby, P. C., V. V. Tryon, B. Chandrasekar, and G. L. Freeman. 1998. Cloning of Syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infect. Immun. 66: 2135-2142.
5. Manna, P. P., D. Bharadwaj, S. Bhattacharya, G. Chakrabarti, D. Basu, K. K. Mallik, and S. Bandyopadhyay. 1993. Impairment of natural killer cell activity in Indian kala-azar: restoration of activity by interleukin 2 but not by γ or γ interferon. Infect. Immun. 61: 3565-3569. (Pubitemid 23223459)
6. Rodrigues, J. V., J. S. Da Silva, and A. Campos-Neto. 1992. Elective inability of spleen antigen presenting cells from Leishmania donovani infected hamsters to mediate specific T cell proliferation to parasite antigens. Parasite Immunol. 14: 49-58.
7. Belkaid, Y., K. F. Hoffmann, S. Mendez, S. Kamhawi, M. C. Udey, T. A. Wynn, and D. L. Sacks. 2001. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 194: 1497-1506. (Pubitemid 33081524)
8. Murray, H. W., C. M. Lu, S. Mauze, S. Freeman, A. L. Moreira, G. Kaplan, and R. L. Coffman. 2002. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 70: 6284-6293.
9. Gama, M. E., J. M. L. Costa, J. C. R. Pereira, C. M. C. Gomes, and C. E. P. Corbett. 2004. Serum cytokine profile in the subclinical form of visceral leishmaniasis. Braz. J. Med. Biol. Res. 37: 129-136. (Pubitemid 38240154)
10. D'Oliveira, A. J., S. R. M. Mosta, A. B. Barbose, M. de la Gloria Orge Orge, and E. M. Carvalho. 1997. Asymptomatic Leishmania chagasi infection in relatives and neighbors of patients with visceral leishmaniasis. Mem. Inst. Oswaldo Cruz, Rio de Janeiro 92: 15-20.
11. Sundar, S., S. G. Reed, S. Sharma, A. Mehrota, and H. W. Murray. 1997. Circulating Th1 cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am. J. Trop. Med. Hyg. 56: 522-526. (Pubitemid 27230074)
12. Hailu, A., T. van der Poll, N. Berge, and P. A. Kager. 2004. Elevated plasma levels of interferon (IFN)-γ, IFN-γinducing cytokines, and IFN-γinducible CXC chemokines in visceral leishmaniasis. Am. J. Trop. Med. Hyg. 71: 561-567. (Pubitemid 39601152)
13. Bourreau, E., G. Prevot, J. Gardon, R. Pradinaud, and P. Launois. 2001. High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment. J. Infect. Dis. 184: 1628-1630. (Pubitemid 33139754)
14. Murray, H. W. 2001. Clinical and experimental advances in treatment in visceral leishmaniasis. Antimicrob. Agents Chemother. 45: 2185-2197. (Pubitemid 32664455)
15. Engwerda, C. R., M. L. Murphy, S. E. Cotterell, S. C. Smelt, and P. M. Kaye. 1998. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur. J. Immunol. 28: 669-680.
16. Murray, H. W., A. L. Moreira, C. M. Lu, J. L. DeVecchio, M. Matsuhashi, X. Ma, and F. P. Heinzel. 2003. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis. J. Infect. Dis. 188: 458-464.
17. Murray, H. W., E. B. Brooks, J. L. DeVecchio, and F. P. Heinzel. 2003. Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 47: 2513-2517. (Pubitemid 36919453)
18. Jha, T. K. 2006. Drug unresponsiveness and combination therapy for kala-azar. Indian J. Med. Res. 123: 389-398.
19. Ghannoum, M. A., and L. B. Rice. 1999. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 12: 501-517.
20. Golenser, J., and A. Domb. 2006. New formulations and derivatives of amphotericin B for treatment of leishmaniasis. Mini. Rev. Med. Chem. 6: 153-162.
21. Chia, J. K., and E. J. McManus. 1990. In vitro tumor necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin B preparations. Antimicrob. Agents Chemother. 34: 906-908.
22. Cleary, J. D., S. W. Chapman, and R. L. Nolan. 1992. Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells. Antimicrob. Agents Chemother. 36: 977-981.
23. Matsumoto, T., M. Kaku, N. Furuya, T. Usui, S. Kohno, K. Tomono, K. Tateda, Y. Hirakata, and K. Yamaguchi. 1993. Amphotericin B-induced resistance to Pseudomonas aeruginosa infection in mice. J. Antibiot. 46: 777-784. (Pubitemid 23199082)
24. Rogers, P. D., J. K. Jenkins, S. W. Chapman, K. Ndebele, B. A. Chapman, and J. D. Cleary. 1998. Amphotericin B activation of human genes encoding for cytokines. J. Infect. Dis. 178: 1726-1733. (Pubitemid 28558146)
25. Chia, J. K., and M. Pollack. 1989. Amphotericin B induces tumor necrosis factor production by murine macrophages. J. Infect. Dis. 159: 113-116. (Pubitemid 19022004)
26. Tokuda, Y., M. Tsuji, M. Yamazaki, S. Kimura, S. Abe, and H. Yamaguchi. 1993. Augmentation of murine tumor necrosis factor production by amphotericin B in vitro and in vivo. Antimicrob. Agents Chemother. 37: 2228-2230. (Pubitemid 23298216)
27. Ghezzi, M. C., G. Raponi, F. Filadoro, and C. Mancini. 1994. The release of TNF-α and IL-6 from human monocytes stimulated by filtrates of Candida albicans after treatment with amphotericin B. J. Antimicrob. Chemother. 33: 1039-1043. (Pubitemid 24170906)
28. Louie, A., A. L. Baltch, R. P. Smith, M. A. Franke, W. J. Ritz, J. K. Singh, and M. A. Gordon. 1995. Fluconazole and amphotericin B antifungal therapies do not negate the protective effect of endogenous tumor necrosis factor in a murine model of fatal disseminated candidiasis. J. Infect. Dis. 171: 406-415.
29. Fujita, H., H. Masuda, T. Nakajima, K. Yada, M. Watanabe, and Y. Kagitani. 1995. [Protective effect of human macrophage colony-stimulating factor on fungal infection (2): in vitro effect of human macrophage colony-stimulating factor on systemic aspergillosis and in vitro effect on the activities of macrophage.] Kansenshogaku Zasshi 69: 582-589.
30. Arning. M., K. O. Kliche, A. H. Heer-Sonderhoff, and A. Wehmeier. 1995. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 38: 459-465. (Pubitemid 26042075)
31. Larabi, M., P. Legrand, M. Appel, S. Gil, M. Lepoivre, J. Devissaguet, F. Puisieux, and G. Barratt. 2001. Reduction of no synthase expression and tumor necrosis factor α production in macrophages by amphotericin B lipid carriers. Antimicrob. Agents Chemother. 45: 553-562. (Pubitemid 32105293)
32. Boggs, J. M., N. H. Chang, and A. Goundalkar. 1991. Liposomal amphotericin B inhibits in vitro T-lymphocyte response to antigen. Antimicrob. Agents Chemother. 35: 879-885.
33. Sundar, S., and M. Rai. 2005. Treatment of visceral leishmaniasis. Exp. Opin. Pharmacother. 6: 2821-2829.
34. De Rossell, R. A., R. J. de Duran, O. Rossell, and A. M. Rodriguez. 1992. Is leishmaniasis ever cured? Trans. R. Soc. Trop. Med. Hyg. 86: 251-253.
35. Mullen, A. B., A. J. Baillie, and K. C. Carter. 1998. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob. Agents Chemother. 42: 2722-2725.
36. Gangneux, J. P., A. Sulahian, Y. J. Garin, and F. Derouin. 1996. Lipid formulations of amphotericin B in the treatment of experimental visceral leishmaniasis due to Leishmania infantum. Trans. R. Soc. Trop. Med. Hyg. 90: 574-577. (Pubitemid 26356647)
37. Afrin, F., T. Dey, K. Anam, and N. Ali. 2001. Leishmanicidal activity of stearylamine-bearing liposomes in vitro. J. Parasitol. 87: 188-193. (Pubitemid 32172366)
38. Dey, T., K. Anam, F. Afrin, and N. Ali. 2000. Antileishmanial activities of stearylamine-bearing liposomes. Antimicrob. Agents Chemother. 44: 1739-1742.
39. Afrin, F., R. Rajesh, K. Anam, M. Gopinath, S. Pal, and N. Ali. 2002. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infect. Immun. 70: 6697-6706. (Pubitemid 35387900)
40. Berman, J. D., W. L. Hanson, W. L. Chapman, C. R. Alving, and G. Lopez-Berestein. 1986. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob. Agents Chemother. 30: 847-851.
41. Lopez-Berestein, G., R. Mehta, R. L. Hopfer, K. Mills, L. Kasi, K. Mehta, V. Fainstein, M. Luna, E. M. Hersh, and R. Juliano. 1983. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J. Infect. Dis. 147: 939-945.
42. Anstead, G. M., B. Chandrasekar, W. Zhao, J. Yang, L. E. Perez, and P. C. Melby. 2001. Malnutrition alters the innate immune response and increases early visceralization following Leishmania donovani infection. Infect. Immun. 69: 4709-4718.
43. Ding, A. H., C. F. Nathan, and D. J. Stuehr. 1988. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J. Immunol. 141: 2407-2412.
44. Pal, S., R. Ravindran, and N. Ali. 2004. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c mice. Antimicrob. Agents Chemother. 48: 3591-3593. (Pubitemid 39129369)
45. Saha, S., S. Mondal, R. Ravindran, S. Bhowmick, D. Modak, S. Mallick, M. Rahman, S. Kar, R. Goswami, S. K. Guha, et al. 2007. IL-10- and TGF-β-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J. Immunol. 179: 5592-5603.
46. Coffman, R. L., D. A. Lebman, and P. Rothman. 1993. Mechanism and regulation of immunoglobulin isotype switching. Adv. Immunol. 54: 229-270.
47. Murray, H. W. 2005. Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis. J. Immunol. 174: 4916-4923. (Pubitemid 40504576)
48. Reyes, E., J. Cardona, A. Prieto, E. D. Bernstein, M. Rodriguez-Zapata, M. J. Pontes, and M. Alvarez-Mon. 2000. Liposomal amphotericin B and amphotericin B-deoxycholate show different immunoregulatory effects on human peripheral blood mononuclear cells. J. Infect. Dis. 181: 2003-2010. (Pubitemid 30416164)
49. Alexander, J., K. C. Carter, N. Al-Fasi, A. Satoskar, and F. Brombacher. 2000. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur. J. Immunol. 30: 2935-2943. (Pubitemid 30786024)
50. Haldar, J. P., S. Ghose, K. C. Saha, and A. C. Ghose. 1983. Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect. Immun. 42: 702-707.
51. Carvalho, E. M., O. Bacellar, C. Brownell, T. Regis, R. L. Coffman, and S. G. Reed. 1994. Restoration of IFN-γ production and lymphocyte proliferation in visceral leishmaniasis. J. Immunol. 152: 5949-5956.
52. Gifawesen, C., and J. P. Farrell. 1989. Comparison of T-cell responses in selflimiting versus progressive visceral Leishmania donovani infections in golden hamsters. Infect. Immun. 57: 3091-3096. (Pubitemid 19240078)
53. Reiner, S. L., and R. M. Locksley. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13: 151-177.
54. Stanley, A. C., and C. R. Engwerda. 2007. Balancing immunity and pathology in visceral leishmaniasis. Immunol. Cell Biol. 85: 138-147.
55. Engwerda, C. R., M. Ato, and P. M. Kaye. 2004. Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis. Trends Parasitol. 20: 524-530.
56. Banerjee, A., J. Roychoudhury, and N. Ali. 2008. Stearylamine-bearing cationic liposomes kill Leishmania parasites through surface exposed negatively charged phosphatidylserine. J. Antimicrob. Chemother. 6: 103-110.
57. Sharma, P., N. Singh, R. Garg, W. Haq, and A. Dube. 2004. Efficacy of human β-casein fragment (54 -59) and its synthetic analogue compound 89/215 against Leishmania donovani in hamsters. Peptides 25: 1873-1881. (Pubitemid 39389181)
58. Little, J. R., T. J. Blanke, F. Valleriote, and G. Medoff. 1978. Immunoadjuvant and antitumor properties of amphotericin B. In Immune Modulation and Control Neoplasia by Adjuvant Therapy. M. A Chiragos, ed. Raven Press, New York, p. 381.
59. Shirley, S. F., and J. R. Little. 1979. Immunopotentiating effects of amphotericin B. II. Enhanced in vitro proliferative responses of murine lymphocytes. J. Immunol. 123: 2883-2889.
60. Marciani, D. J. 2003. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov. Today 8: 934-943. (Pubitemid 37230013)
61. Jiang, Z. H., and R. R. Koganty. 2003. Synthetic vaccines: the role of adjuvants in immune targeting. Curr. Med. Chem. 10: 1423-1439.
62. Moingeon, P., J. Haensler, and A. Lindberg. 2001. Towards the rational design of Th1 adjuvants. Vaccine 19: 4363-4372. (Pubitemid 32718658)
63. Bellocchio, S., R. Gaziano, S. Bozza, G. Rossi, C. Montagnoli, K. Perruccio, M. Calvitti, L. Pitzurra, and L. Romani. 2005. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J. Antimicrob. Chemother. 55: 214-222. (Pubitemid 40331148)
64. Seder, R. A., and A. V. Hill. 2000. Vaccines against intracellular infections requiring cellular immunity. Nature 406: 793-798.
65. Corradin, S. B., N. Fasel, Y. Buchmuller-Rouiller, A. Ransijn, J. Smith, and J. Mauel. 1993. Induction of macrophage nitric oxide production by interferon-γ and tumor necrosis factor-α is enhanced by interleukin-10. Eur. J. Immunol. 23: 2045-2048. (Pubitemid 23236810)
66. + T cell response. J. Exp. Med. 181: 961-971.
67. Liew, F. Y., and C. A. O'Donnell. 1993. Immunology of leishmaniasis. Adv. Parasitol. 32: 161-259.
68. + cells in experimental visceral leishmaniasis. J. Immunol. 140: 3971-3977.
69. McElrath, M. J., H. W. Murray, and Z. A. Cohn. 1988. The dynamics of granuloma formation in experimental visceral leishmaniasis. J. Exp. Med. 167: 1927-1937. (Pubitemid 18174281)
70. Gurunathan, S., C. Prussin, D. L. Sacks, and R. A. Seder. 1998. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 12: 1409-1415. (Pubitemid 28553464)
71. Stobie, L., S. Gurunathan, C. Prussin, D. L. Sacks, N. Glaichenhaus, C. Y. Wu, and R. A. Seder. 2000. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc. Natl. Acad. Sci. USA 97: 8427-8432. (Pubitemid 30639689)
72. Matsuo, K., H. Hotokezaka, N. Ohara, Y. Fujimura, A. Yoshimura, Y. Okada, Y. Hara, N. Yoshida, and K. Nakayama. 2006. Analysis of amphotericin Binduced cell signaling with chemical inhibitors of signaling molecules. Microbiol. Immunol. 50: 337-347. (Pubitemid 46277500)
73. Bhattacharyya, S., S. Ghosh, P. L. Jhonson, S. K. Bhattacharya, and S. Majumdar. 2001. Immunomodulatory role of interleukin-10 in visceral leishmaniasis: defective activation of protein kinase C-mediated signal transduction events. Infect. Immun. 69: 1499-1507. (Pubitemid 32187601)
74. Mathur, R. K., A. Awasthi, P. Wadhone, B. Ramanamurthy, and B. Saha. 2004. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat. Med. 10: 540-544.